Tive to HIV. [12] Drug concentration is also affected by adherence; while iPrExhighest rate among participants living in Ecuador (9.7 per 100 person-years) and the lowest rate among participants living in Thailand (1.7 per 100 person-years). The only behavioral factor associated with time to HSV-2 incidence was ncRAI in the past three months (HR 2.0, 95 CI: 1.4-3.0; P,0.001). In multivariable ana
Tive to HIV. [12] Drug concentration is also affected by adherence; while iPrExhighest rate among participants living in Ecuador (9.7 per 100 person-years) and the lowest rate among participants living in Thailand (1.7 per 100 person-years). The only behavioral factor associated with time to HSV-2 incidence was ncRAI in the past three months (HR 2.0, 95 CI: 1.4-3.0; P,0.001). In multivariable ana
Nt HSV-2 infection in iPrEx was receptive anal intercourse without a condom, a finding that has been reported in several studies of behavioral risk factors for HSV-2 acquisition in MSM. [18,19,20] The rectal mucosa and cervicovaginal mucosa may differ in their susceptibility to HSV-2 infection. Additionally, although oral dosing of tenofovir achieves drug concentrations that are 20?00 times higher
Nt HSV-2 infection in iPrEx was receptive anal intercourse without a condom, a finding that has been reported in several studies of behavioral risk factors for HSV-2 acquisition in MSM. [18,19,20] The rectal mucosa and cervicovaginal mucosa may differ in their susceptibility to HSV-2 infection. Additionally, although oral dosing of tenofovir achieves drug concentrations that are 20?00 times higher
Version; however, this finding was not confirmed by ulcers identified during STI examinations and may have included ulcers of nonherpetic etiologies. In contrast to the 51 reduction in HSV-2 incidence among women randomized to use a 1 tenofovir topical gel in CAPRISA 004, [9] our results suggest that tenofovir in daily oral FTC/TDF may reduce the occurrence of ulcers in individuals with HSV-2 in
Version; however, this finding was not confirmed by ulcers identified during STI examinations and may have included ulcers of nonherpetic etiologies. In contrast to the 51 reduction in HSV-2 incidence among women randomized to use a 1 tenofovir topical gel in CAPRISA 004, [9] our results suggest that tenofovir in daily oral FTC/TDF may reduce the occurrence of ulcers in individuals with HSV-2 in
Used acyclovir or valacyclovir during study follow-up.HSV-2 prevalenceOf the 2,499 participants, 1383 (55.3 ) tested negative for HSV-2 at baseline, 892 (35.7 ) tested positive, 223 (8.9 ) had indeterminate tests, and one test was not done. Of the 223 with indeterminate tests at baseline, 114 (51.1 ) tested positive for HSV-2 infection at some point during follow-up. Factors associated with testin
Lcer was identified, and 5.6 had 1 STI examination during which a groin ulcer was identified after HIV seroconversion, and thus after stopping study drug. The proportions with each type of ulcer did not differ between participants in the FTC/TDF arm and participants in the placebo arm. Finally, the iPrEx protocol did not use the HSV-2 test manufacturer's suggested cutoffs for indeterminate (IR